MedTrace Logo

Autologous Bone Marrow Mononuclear Cells Therapy in Diabetic Lower Limb Ischemia

NCT01937416 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2013-12-04

No results posted yet for this study

Summary

This study is to evaluate the safety and efficacy of autologous bone marrow mononuclear cells transplantation in diabetic patients with lower limb ischemia.

Conditions

Interventions

BIOLOGICAL

autologous bone marrow mononuclear cells

Bone marrow was taken from patient oneself and mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation. Bone marrow mononuclear cells were transplanted into ischemia regions of lower limb through intramuscular injection.

Sponsors & Collaborators

  • Hebei Medical University

    lead OTHER

Principal Investigators

  • Baoyong Yan, Doctor · The First Hospital of Hebei Medical University

  • Huimin Zhou, doctor · The First Hospital of Hebei Medical University

  • Xu Han, master · The First Hospital of Hebei Medical University

  • Quanhai Li, doctor · The First Hospital of Hebei Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-09-30
Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01937416 on ClinicalTrials.gov